See more : Ambar Protein Industries Limited (AMBARPIL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Alopexx, Inc. (ALPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alopexx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- The Planting Hope Company Inc. (MYLKF) Income Statement Analysis – Financial Results
- New England Power Company PFD 6% (NEWEN) Income Statement Analysis – Financial Results
- Ricksoft Co., Ltd. (4429.T) Income Statement Analysis – Financial Results
- Widgie Nickel Limited (WIN.AX) Income Statement Analysis – Financial Results
- Advanced Micro-Fabrication Equipment Inc. China (688012.SS) Income Statement Analysis – Financial Results
Alopexx, Inc. (ALPX)
About Alopexx, Inc.
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 188.62K | 1.35M |
| General & Administrative | 714.79K | 314.01K |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 714.79K | 314.01K |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 903.41K | 1.67M |
| Cost & Expenses | 903.41K | 1.67M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 53.55K | 34.39K |
| Depreciation & Amortization | 0.00 | 206.30K |
| EBITDA | -903.41K | -1.67M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -903.41K | -1.67M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -53.55K | -34.39K |
| Income Before Tax | -956.95K | -1.70M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 53.55K | 34.39K |
| Net Income | -1.01M | -1.74M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -0.10 | -0.14 |
| EPS Diluted | -0.10 | -0.14 |
| Weighted Avg Shares Out | 9.69M | 12.53M |
| Weighted Avg Shares Out (Dil) | 9.69M | 12.53M |
Will Alopexx (ALPX) Stock Be the Next Hot IPO?
Alopexx To Raise ~$15m IPO With Ambition To Drive Blockbuster Sales As Prevnar's Partner
Source: https://incomestatements.info
Category: Stock Reports